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Abstract
Introduction Septic shock is associated with increased microvascular permeability. As a model for 
study of the pathophysiology of sepsis, endotoxin administration to humans has facilitated research into 
inflammation, coagulation and cardiovascular effects. The present study was undertaken to determine 
whether endotoxin administration to human volunteers can be used as a model to study the sepsis- 
associated increase in microvascular permeability.
Methods In an open intervention study conducted in a university medical centre, 16 healthy volunteers 
were evaluated in the research unit of the intensive care unit. Eight were administered endotoxin 
intravenously (2 ng/kg Escherichia coli O113) and eight served as control individuals. Microvascular 
permeability was assessed before and 5 hours after the administration of endotoxin (n =  8) or placebo 
(n =  8) by three different methods: transcapillary escape rate of I125-albumin; venous occlusion strain- 
gauge plethysmography to determine the filtration capacity; and bioelectrical impedance analysis to 
determine the extracellular and total body water.
Results Administration of endotoxin resulted in the expected increases in proinflammatory cytokines, 
temperature, flu-like symptoms and cardiovascular changes. All changes were significantly different 
from those in the control group. In the endotoxin group all microvascular permeability parameters 
remained unchanged from baseline: transcapillary escape rate of I125-albumin changed from 7.2 ±  0.6 
to 7.7 ±  0.9%/hour; filtration capacity changed from 5.0 ±  0.3 to 4.2 ± 0.4 ml/min per 100 ml mmHg 
x 10-3; and extracellular/total body water changed from 0.42 ± 0.01 to 0.40 ± 0.01 l/l (all differences 
not significant).
Conclusion Although experimental human endotoxaemia is frequently used as a model to study sepsis- 
associated pathophysiology, an endotoxin-induced increase in microvascular permeability in vivo could 
not be detected using three different methods. Endotoxin administration to human volunteers is not 
suitable as a model in which to study changes in microvascular permeability.
In t r o d u c t io n  acterized by an increase in microvascular permeability, which
Sepsis is the leading cause of mortality in noncardiac intensive accounts for the extravasation of macromolecules and fluid
care units, resulting in an estimated mortality of 200,000 from the plasma to the tissues. The impaired diffusion of oxy-
patients per year in the USA alone [1]. Sepsis is notably char- gen to cells as a result of the extracellular oedema appears to
BIA =  bioelectrical impedance analysis; ECW =  extracellular water; IL =  interleukin; Kf =  filtration capacity; LPS =  lipopolysaccharide; TER-alb =  tran­
scapillary escape rate of I125-albumin; TNF =  tumour necrosis factor; TBW =  total body water; VCP =  venous congestion plethysmography. R157
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be a critical factor in the development of multiple organ failure 
[2,3]. Few studies have been conducted in humans to examine 
the mechanism that underlies the sepsis-associated increase 
in microvascular permeability.
Endotoxin is among the principal bacterial components that 
interacts with the host during Gram-negative sepsis [4]. 
Administration of endotoxin to humans is an appropriate model 
in which to investigate acute inflammatory responses (activa­
tion of cytokines and coagulation pathways) and to evaluate 
novel therapeutic interventions [5]. In vitro, exposure of human 
endothelial cells to endotoxin induces an increase in permea­
bility [6], and in vivo an increase in microvascular permeability 
is among the major manifestations observed in animal endo- 
toxaemia [7-12]. In humans, microvascular permeability can be 
assessed by plasma disappearance of a tracer (e.g. I125-albu- 
min), changes in tissue volume caused by an imposed hydro­
static pressure and changes in bio-impedance. These 
methods were validated for the detection of a modest increase 
in microvascular permeability in patients with various diseases 
[13-17] and, more relevant to our study, patients with sepsis 
or septic shock [18-20]. In septic patients, transcapillary 
escape rate of albumin varies from 6.7%/hour [21] to 13.4%/ 
hour [18], whereas permeability measured using venous con­
gestion plethysmography (VCP) ranged from 6.1 ml/min per 
100 ml mmHg x  10'3 [19] to 9.3 ml/min per 100 ml mmHg x 
10-3 [22].
The present study was undertaken to determine whether 
endotoxin administration to human volunteers can be 
employed as a model in which to study the sepsis-associated 
increase in microvascular permeability.
Materials and methods 
Subjects
After approval had been granted by the local ethics committee, 
16 nonsmoking individuals gave written informed consent to 
participate in the study. Those who were taking prescription 
drugs or asprin or other nonsteroidal anti-inflammatory drugs 
were excluded (except for oral anticontraceptives). Screening 
of the participants before the test revealed no abnormalities in 
medical history or physical examination. Routine laboratory 
tests and electrocardiograms were normal. All participants 
were HIV and hepatitis B negative. They had not suffered a 
febrile illness within the 2 weeks preceding the study. Ten 
hours before the experiment, the participants refrained from 
consuming caffeine, alcohol and food.
Study design and procedures
Heart rate was continuously monitored using a three-lead 
electrogradiograph. An intra-arterial catheter in the radial 
artery permitted arterial blood sampling as well as continuous 
monitoring of blood pressure throughout the experiment. Fore­
arm blood flow was measured in both arms using VCP, as 
described previously [23]. All participant received an intrave­
nous infusion of a glucose/saline solution (2.5% glucose, 
0.45% saline; 75 cm3/hour) via a cannula in an antecubital 
vein. At baseline, purified lipopolysaccharide (LPS) prepared 
from Escherichia coli O113 was injected intravenously (2 ng/ 
kg) over 1 -2  min in eight individuals, followed by 5 ml normal 
saline to ensure complete delivery. Another eight served as 
control individuals and received NaCl 0.9% instead of endo­
toxin in an equivalent volume. Because of obvious sympto­
matic changes after infusion of endotoxin, neither the 
volunteers nor the staff members were blinded to the study 
protocol.
The course over time of temperature, C-reactive protein, and 
plasma levels of tumour necrosis factor (TNF)-a and inter­
leukin (IL)-1 p [24] were monitored to confirm the inflammatory 
effects of endotoxin administration.
Transcapillary escape rate of I125albumin
Microvascular permeability determined by the transcapillary 
escape rate of I125-albumin (TER-alb) was measured at base­
line and 5 hours after endotoxin administration, when haemo- 
dynamic changes are at their maximum [25]. I125 labelled 
albumin solution of 2 |iC i (baseline) and 6 |iC i (at 5 hours) in
5 cm3 normal saline were given as an intravenous bolus injec­
tion followed by 5 cm3 normal saline. The second dose is 
higher to overcome the background signal of the first dose. 
Arterial blood samples were drawn at baseline, and at 5, 10, 
15, 20, 30, 45 and 60 min. Plasma radioactivity was measured 
in each sample using a scintillation detector (automatic y- 
counter; 1480 Wizard 3", Wallac, Turku, Finland).
Venous congestion plethysmography
Microvascular permeability was also determined by VCP, in 
accordance with methods fully described previously [26,27]. 
Microvascular filtration capacity (Kf) -  an index of vascular per­
meability -  was measured using a protocol in which a series of 
eight small (10 mmHg) cumulative pressure steps were 
applied to venous congestion cuffs placed around both upper 
arms. Kf was estimated from alterations in forearm circumfer­
ence due to the pressures applied, using the Filtrass strain 
gauge plethysmograph (Filtrass Angio, DOMED, Munich, Ger­
many) [27]. Using this system, no change in the recorded sig­
nal is observed until ambient venous pressure in the arm is 
exceeded. At congestion cuff pressures greater than this 
value, each additional pressure increment causes a change in 
forearm volume that is attributed to vascular filling. When the 
congestion cuff pressure exceeds the isovolumetric venous 
pressure, a steady state change in volume is observed, reflect­
ing fluid filtration. Kf reflects the product of the area available 
for fluid filtration and the permeability per unit surface area. 
Computer-based analysis enables differentiation between vol­
ume and filtration responses [28]. The value of Kf is deter­
mined by linear regression of the fluid filtration as a function of 
the cuff pressure. The slope of this relationship is Kf and the 
units are expressed as KfU (ml/min per 100 ml mmHg x  10'3)
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Table 1
Demographic characteristics of the participants
Parameter Endotoxin group Control group
n (male/female) 8 (4/4) 8 (4/4)
Age (years) 23.9 ± 1.0 22.5 ± 0.8
Length (cm) 176 ± 5 183 ± 3
Weight (kg) 71.8 ± 4.9 70.1 ± 3.6
BMI (kg/m2) 23.0 ± 0.7 20.9 ± 0.8
SBP/DBP (mmHg) 127 ± 2/80 ± 3 119 ± 3/73 ± 3
Forearm volume (ml) 1019 ± 95 931 ± 67
Data are expressed as mean ± standard deviation. There were no significant differences between the groups. BMI, body mass index; DBP, 
diastolic blood pressure; SBP, systolic blood pressure.
[28]. The files were recorded and saved for subsequent offline 
analysis. Kf measurements were conducted before, and 4.5 
hours and 22 hours after the administration of endotoxin or 
normal saline.
Bioelectrical impedance analysis
In septic patients, fluid shifts from intracellular water to extra­
cellular water (ECW) and an increase in total body water 
(TBW) occur because of an altered cellular membrane func­
tion, resulting in the formation of oedema. Bioelectrical imped­
ance analysis (BIA) can estimate body composition 
parameters and has been used to estimate body water distri­
bution and cellular membrane function in healthy individuals
[29] and intensive care patients [20,30-33]. The principles of 
bioelectrical impedance postulate that resistance (R) is the 
opposition of TBW  and electrolytes to the flow of an alternat­
ing current of low amplitude (800 |iA) and high frequency (50 
kHz). Reactance is the capacitance produced by tissue inter­
faces and cell membranes. An increase in microvascular per­
meability and an altered membrane function result in the 
formation of oedema, which decreases the resistance and 
reactance to an alternating electric current throughout the 
body. ECW will increase in relation to TBW, and reactance/ 
resistance will decrease. BIA was performed using a body 
composition analyzer (Akern Srl, Florence, Italy). This device 
employs four-electrode polarization and measures the resist­
ance and reactance of a conductor to application of an alter­
nating electric current of 800 |iA  and 50 kHz. All 
measurements were made with the patient supine, with their 
arms relaxed at their sides but not touching their body, and 
with their thighs slightly separated. Electrodes were placed on 
the dorsal surface of the skin of the wrist and ankle, with the 
detector electrodes applied along the articulation bisecting 
line of both joints. BIA was performed at baseline and 4, 6, 8 
and 22 hours after endotoxin administration.
Drugs and solutions
All solutions were freshly prepared on the day of the experi­
ment. Endotoxin from Escherichia coli (batch 0:113, lot
R159
G2B274) was obtained from US Pharmacopia Convention 
(Rockville, MD, USA) and dissolved in normal saline 0.9% to a 
concentration of 200 EU/ml (0.1 ml/kg). I125-albumin (Iodi- 
nated [125I] Human Serum Albumin; code IM 17 P) was 
obtained from Amersham International (Amersham, UK).
Data analysis, calculations and statistics
Power analysis was based on clinically relevant changes in 
TER-Alb. In a previous study using the TER-alb method, we 
found a standard deviation ranging from 1.5% to 2.5%. An 
increase in transcapillary escape rate of 2.5% was considered 
clinically relevant. W ith an estimated standard deviation of 2% 
and a  =  0.05, we calculated that a sample size of seven indi­
viduals per group would be needed to achieve a power of 
95%. Therefore, eight individuals per group were included.
TER-alb was calculated and expressed as the percentage dis­
appearance per hour. Fluid filtration capacity (Kf) was deter­
mined by venous occlusion plethysmography in both forearms 
and averaged. The mean Kf was used for further calculations. 
A change in the ratio of ECW /TBW  was taken to give an 
impression of microvascular permeability, using BIA.
Student's t-tests or analysis of variance with repeated meas­
ures were used for the assessment of the effects of endotoxin 
on microvascular permeability parameters. All data are 
expressed as mean ±  standard error of the mean of n experi­
ments unless otherwise stated. P  <  0.05 was considered sta­
tistically significant.
Results
Demographic characteristics of the participants are presented 
in Table 1. There were no significant differences between the 
groups.
Changes in clinical and inflammatory parameters
The first flu-like symptoms (headache, nausea, chills) occurred 
in the endotoxin-treated group between 55 and 90 min after 
LPS injection. Body temperature started to rise 1 hour after
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Figure 1
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Changes in inflammatory parameters. Administration of endotoxin (n =  
8; 2 ng/kg) resulted in a marked increase in tumour necrosis factor 
(TNF)-a (closed squares, left axis) and IL-1 p (open squares, right axis). 
In control individuals cytokine levels remained below the detection limit 
(n =  8; data not shown). Cytokine release was associated with fever 
and an increase in C-reactive protein (CRP; endotoxin group, closed 
squares; control group, open circles). Data are expressed as means ± 
standard error of the mean. The P values in the figure refer to the differ­
ence between endotoxin and control groups as analyzed using analysis 
of variance with repeated measures over the complete curve.
endotoxin administration to a maximum of 38.7 ±  0.3°C at 4 
hours versus 36.9 ±  0.2°C in the control group (P <  0.001). 
At 8 hours all clinical symptoms had declined to control values. 
The clinical onset of inflammation was accompanied by a sud­
den rise in TNF-a plasma levels at 60 min (373 ±  71 pg/ml), 
which reached its zenith at 90 min (856 ±  158 pg/ml), closely 
followed by a rise in IL-1 p that was maximal at 120 min (23.9 
±  2.2 pg/ml). C-reactive protein increased from under 5 mg/ 
ml at baseline to 22.3 ±  1.4 mg/ml at 12 hours after endotoxin 
administration and reached its maximum at 22 hours (38.9 ±
3.0 mg/ml). In the control individuals no elevations in tempera­
ture (from 36.9 ±  0.1 to 37.0 ±  0.1°C), clinical symptoms, 
cytokine levels (TNF-a <8  pg/ml, IL-1 p < 8  pg/ml) or C-reative 
protein (<5 mg/ml) were observed (Fig. 1).
Changes in haemodynamic parameters
Figure 2 shows the course of heart rate, mean arterial pressure 
and forearm blood flow in the endotoxin and control group. In 
the control group the mean arterial blood pressure decreased 
from 88 to 80 mmHg at 6 hours (P =  0.035); the blood pres­
sure decreased significantly more in the individuals adminis-
Figure 2
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Changes in haemodynamic parameters. Administration of endotoxin (2 
ng/kg; n =  8; closed squares) resulted in a significant increase in heart 
rate (HR; measured using electrocardiography; P <  0.0001), a signifi­
cant decrease in mean arterial pressure (MAP; measured intra-arterially; 
P <  0.0001) and a significant increase in forearm blood flow (FBF; 
measured using venous occlusion plethysmography; P =  0.01 8). HR 
and FBF did not change significantly in the control group (open circles; 
n =  8), whereas MAP decreased (P =  0.035). MAP decreased signifi­
cantly more in the endotoxin group than in the control group (P =
0.002). These changes demonstrate that endotoxin induces a vasodila- 
tory state. Data are expressed as means ± standard error of the mean. 
The P values in the figure refer to the difference between endotoxin and 
control group as analyzed using analysis of variance with repeated 
measures over the complete curve.
tered LPS (from 96 ±  3 mmHg to 79 ±  4 mmHg at 6 hours, P 
<  0.0001; difference from control individuals: P  =  0.002). 
Heart rate remained unchanged in the control group (from 66 
±  4 to 65 ±  2 beats/min; not significant) and increased from 
63 ±  3 to 91 ±  3 beats/min at 6 hours in the LPS group (P <  
0.0001). Forearm blood flow increased from 3.7 ±  0.6 to 6.8 
±  1.1 ml/min per dl at 6 hours (P =  0.018) in the endotoxin 
group, but remained unchanged in the control group (3.8 ±
0.8 versus 4.4 ±  0.9 ml/min per dl; not significant).
Changes in microvascular permeability parameters
In neither the endotoxin group nor the control group were sig­
nificant alterations in microvascular permeability parameters
R160
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Figure 3
Changes in microvascular permeability parameters. Microvascular per­
meability parameters were measured using transcapillary escape rate of 
I125-albumin (TER-alb), venous congestion plethysmography (VCP) and 
bioelectrical impedance analysis (BIA). There were no changes in 
microvascular permeability as measured using all three parameters in 
either the endotoxin group (n =  8; 2 ng/kg; closed squares) or in the 
control group (n =  8; open circles). Data are expressed as means ± 
standard error of the mean. ECW, extracellular water; TBW, total body 
water.
detected. In the endotoxin group TER-alb was 7.2 ±  0.6%/ 
hour before and 7.7 ±  0.9%/hour at 4.5 hours after endotoxin 
administration (not significant); Kf remained unchanged (from
5.0 ±  0.3 to 4.2 ±  0.4 ml/min per 100 ml mmHg x  10-3; not 
significant); and ECW /TBW , as measured by BIA, did not 
change (from 0.42 ±  0.01 l/l to 0.40 ±  0.01 l/l; not significant). 
Also, no significant changes in microvascular permeability 
parameters were found in the control group (all not significant: 
TER-alb from 9.08 ±  1.28 to 10.38 ±  0.63%/hour; Kf from 
4.14 ±  0.42 to 5.17 ±  0.39 ml/min per 100 ml mmHg x  10-3; 
and ECW /TBW  from 0.43 ±  0.01 l/l to 0.42 ±  0.01 l/l). The 
effect of endotoxin on microvascular parameters is shown in 
Fig. 3.
Discussion
Although administration of endotoxin to human volunteers has 
facilitated sepsis-associated research, the present study dem­
onstrates that human experimental endotoxaemia is not a suit­
able model in which to study sepsis-induced changes in 
microvascular permeability. In a negative study the first issue 
to address is methodology. W e conducted the present study 
with all three methods that are available for human in vivo 
experiments. Differences in microvascular permeability have 
been detected in various other diseases with these methods 
[13-17]. In septic patients an increase in Kf was demonstrated 
with TER-alb [18], VCP [19] and BIA [20]. In view of the ability
of these methods to detect differences in microvascular per­
meability and the consistently negative findings of all three 
methods used in this endotoxin study, we believe our results 
are valid.
There are several possible reasons for our negative findings. 
First, the inflammatory stimulus might not have been suffi­
ciently powerful. Endotoxin is known to stimulate the immune 
system in a dose-dependent manner [25]. Indeed, a marked 
increase in permeability in  vivo has previously been shown in, 
for example, cats after intravenous administration of 1 mg/kg 
endotoxin [10]. On one occasion, an autointoxication with 1 
mg of Salmonella endotoxin resulted in profound vasodilatory 
shock and a 15 l cumulative fluid balance over 72 hours in a 
laboratory worker [34]. This demonstrates unequivocally that 
high doses of endotoxin can cause shock and vascular leak­
age. In human volunteers an endotoxin concentration of 4 ng/ 
kg is considered the maximal tolerable dose. The concentra­
tion of 2 ng/kg is widely applied and results in systemic inflam­
mation, activation of coagulation pathways and distinct 
haemodynamic changes. Although the rise in proinflammatory 
cytokines is dose dependent, studies that used 4 ng/kg LPS 
found changes in clinical parameters similar to those reported 
here (e.g. rise in body temperature and fall in blood pressure) 
[35]. In the individuals included in the present study (who 
received 2 ng/kg) the flu-like symptoms, rise in body tempera­
ture, rise in heart rate, fall in blood pressure and rise in C-reac­
tive protein were considerable; we therefore believe that the 
inflammatory stimulus was adequate. Also, the TNF-a and IL- 
1p concentrations in these individuals exceeded considerably 
the threshold levels of 50 pg/ml and 20 pg/ml, respectively, 
that are necessary to increase permeability significantly in vitro 
[6].
Naturally, it remains difficult for many reasons to compare an 
in vitro study in endothelial cells of large vessels with our in 
vivo experiment. The human endotoxaemia model is currently 
the only available in vivo human model that mimics Gram-neg­
ative sepsis. Whereas in experimental endotoxaemia the stim­
ulus is restricted to LPS, other (non-LPS) bacterial 
components are also of importance for the induction of 
cytokines and the inflammatory response [36] and possibly the 
induction of vascular leakage. These differences could repre­
sent the reason why therapies directed at endotoxaemia itself 
are not of benefit in patients with septic shock [37]. However, 
as a model, the changes in haemodynamics that occur during 
human endotoxaemia are similar to those observed in septic 
shock, and suggest that endotoxin is a major mediator of the 
cardiovascular dysfunction that occurs in this condition [35].
A second possible reason for our negative findings is that not 
only the peak concentration of cytokines but also the duration 
of the increased level of the inflammatory mediators may be 
important in the pathophysiology of oedema formation in sep­
sis. The stimulus caused by a single bolus injection of endo­
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toxin may be too short to induce an increase in microvascular 
permeability. The induction of capillary leakage in vitro was 
accomplished after incubation with endotoxin or cytokines for
6 hours [6]. Also, in pre-eclampsia a sustained rise in plasma 
cytokines is associated with an increase in microvascular per­
meability, suggesting a causal relationship [38]. However, 
although in some cases of sepsis in humans (e.g. meningococ­
cal disease) elevated serum levels of TNF-a have been found 
in up to 90% of patients [39], several other clinical studies in 
septic patients reported only minimally elevated or undetecta­
ble levels of TNF-a [40,41]. Because these patients exhibit an 
overt increase in microvascular permeability, sustained high 
cytokine levels are apparently not mandatory for the develop­
ment of oedema.
A third reason is that the timing of the measurements might not 
have been optimal for the detection of changes in permeability. 
In previous studies maximal changes in haemodynamic param­
eters were found between 2 and 6 hours after administration 
of endotoxin [35]. Because these vascular changes can partly 
be accounted for by endothelial dysfunction [42], we opted to 
measure microvascular permeability in the same time window. 
The possibility that an increase in permeability occurred out­
side the time window of interest appears unlikely because BIA 
was unchanged at five time points during the experiment, and 
Kf was also unaltered at 22 hours after endotoxin administra­
tion. Timing may be of critical importance because an acceler­
ated plasma efflux of albumin was only observed during the 
early phase of sepsis in rats [43]. Also, late-acting cytokines 
(e.g. high mobility group protein 1) remain elevated for 16 -32  
hours after the administration of endotoxin and may play a role 
in the capillary leak found in septic patients. This and possibly 
other mediators were not measured during our experiment. 
Again, BIA and VCP measurements after 22 hours did not 
reveal an increase in vascular permeability in our experiments, 
suggesting that a possible late increase in vascular permeabil­
ity was not missed.
Finally, oedema formation may differ from tissue to tissue and 
from organ to organ. In human endotoxaemia increases in 
intestinal permeability [44] and alveolar epithelial permeability 
[45] were previously demonstrated. In contrast, human endo- 
toxaemia did not induce an increase in the ocular blood-aque­
ous barrier [46]. W ith the TER-alb and BIA whole body 
permeability is assessed, whereas the Filtrass strain gauge 
plethysmograph focuses on the forearms. An increase in 
microvascular permeability in, for example, the lungs was not 
specifically assessed, but if it was present it was insufficient to 
affect whole body permeability. Administration of iodated albu­
min as a measure of capillary leak may vary with hydration sta­
tus, and albumin molecules might be too large to be useful as 
a sensitive permeability marker. However, these problems are 
overcome with the use of VCP. W e believe that fluid loading 
would not have altered transcappilary leakage, because with 
the VCP method a venous occlusion pressure is applied to the
forearms, so that vascular permeability is measured independ­
ent of the volume status of the subject. The suggestion that 
permeability might have been increased for smaller molecules 
than albumin can be ruled out for the same reason.
In summary, we do not believe that the methods used, the tim­
ing of the permeability measurements, or the absolute maximal 
cytokine concentrations can account for the observed lack of 
effect of endotoxin on microvascular permeability in humans. 
However, the short duration of cytokine increase possibly 
played a role.
Conclusion
Although endotoxin administration to humans has proven to be 
a valuable model for studying systemic inflammation and coag­
ulation, this model cannot be used to investigate the patho­
physiological mechanisms that underlie capillary leakage in 
sepsis or to evaluate pharmacological interventions aimed at 
attenuating the increase in microvascular permeability.
Key messages
• Endotoxin administration to humans is a valuable model 
in which to investigate inflammatory and haemodynamic 
mechanisms in sepsis.
• Endotoxin administration to humans does not affect 
microvascular permeability measured using TER-alb,
VCP and BIA.
• Endotoxin administration can not be used as a model to 
study the pathopysiological mechanisms that underlie 
capillary leakage in sepsis, or to evaluate the pharmaco­
logical interventions aimed at restoring normal microvas- 
cular permeability.
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